GlaxoSmithKline plc: Next Stop 1,600P

GlaxoSmithKline plc (LON: GSK) could be on track to hit 1,600p.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

After nearly a year of giving GlaxoSmithKline (LSE: GSK) a wide berth, the market finally seems to be waking up to the company’s potential. Indeed, so far this year Glaxo’s shares have outperformed the broader FTSE 100 by 8% as investors are beginning to buy into the company’s turnaround story and wake up to the value locked away within Glaxo’s corporate structure. 

The number of investors calling for a break-up of the pharma giant has also increased. The UK’s best-known fund manager, Neil Woodford has been calling for a break-up of Glaxo for some time, but he’s been joined by the London arm of Och-Ziff Capital Management, the activist hedge fund headquartered in New York, which has built a stake of 0.5% in the company.

A break-up could unlock value for Glaxo’s shareholders but even if the company’s management refuses to go down this route, its earnings are set to return to growth this year after a year of stagnation and this should re-ignite interest in the company’s shares. 

Back to growth

Glaxo’s management expects the company’s revenue to rise at a compound annual growth rate of “low-to-mid single digits” over the five years from 2016 to 2020.

Over the same period, core earnings per share are expected to expand at a rate in the “mid-to-high single digits”. Admittedly, a large part of Glaxo’s earnings growth will come from cost savings. The group is on track to achieve annualised cost savings of £3bn by the end of 2017, but these savings should help streamline the group’s business. 

Still, City analysts expect Glaxo to report earnings per share growth of 11% for 2016, recovering some of the ground lost last year. Based on these forecasts from the City, Glaxo is trading at a forward P/E of 15.8. Most of the company’s peers trade at a P/E in the low-20s. As Glaxo returns to growth, the market should re-rate the company and Glaxo’s shares should attract a higher valuation. 

A great income stock

So, over the next year as Glaxo racks up its first growth in five years, investors should begin to view the company in a more positive light once again. What’s more, Glaxo is on track to issue a special dividend of around 20p per share during the first quarter of this year. 

The special dividend is connected to Glaxo’s asset swap with peer Novartis. As part of the transaction, Glaxo announced that it would be returning £1bn to shareholders in the form of a special dividend along with the company’s regular fourth quarter payout that’s scheduled for Thursday 14 April 2016. The shares will go ex-dividend on Thursday 18 February 2016. Together, the regular and special payout will amount to approximately 40p per share, putting Glaxo on track to return 100p per share to investors this year and giving a yield of 7%. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »